Document Detail


Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.
MedLine Citation:
PMID:  11085335     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ibogaine (IBO) is a plant-derived alkaloid that is being evaluated as a possible medication for substance use disorders. When administered peripherally to monkeys and humans, IBO is rapidly converted to an o-demethylated metabolite, 12-hydroxyibogamine (NORIBO). We have found in rats that peak blood levels of NORIBO can exceed those of the parent compound, and NORIBO persists in the bloodstream for at least 24 h. Surprisingly few studies have examined the in vivo biological activity of NORIBO. In the present series of experiments, we compared the effects of intravenous (i.v.) administration of IBO and NORIBO (1 and 10 mg/kg) on unconditioned behaviors, circulating stress hormones, and extracellular levels of dopamine (DA) and serotonin (5-HT) in the nucleus accumbens of male rats. IBO caused dose-related increases in tremors and forepaw treading, whereas NORIBO did not. Both IBO and NORIBO produced significant elevations in plasma corticosterone and prolactin, but IBO was more potent as a stimulator of corticosterone secretion. Neither drug affected extracellular DA levels in the nucleus accumbens. However, both IBO and NORIBO increased extracellular 5-HT levels, and NORIBO was more potent in this regard. The present data demonstrate that NORIBO is biologically active and undoubtedly contributes to the in vivo pharmacological profile of IBO in rats. Most importantly, NORIBO appears less likely to produce the adverse effects associated with IBO (i.e., tremors and stress-axis activation), suggesting that the metabolite may be a safer alternative for medication development.
Authors:
M H Baumann; J P Pablo; S F Ali; R B Rothman; D C Mash
Related Documents :
2590845 - Post-mortem dopamine dynamics assessed by voltammetry and microdialysis.
9184115 - Long-term reciprocal changes in dopamine levels in prefrontal cortex versus nucleus acc...
2299355 - Vesicular and ganglionic norepinephrine in the rat: progressive increase with age.
18796185 - Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: impl...
466425 - Catecholamines and convulsions.
16051715 - Role of parasympathetic overactivity in water immersion stress-induced gastric mucosal ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  914     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2005-11-04     Completed Date:  2006-01-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  354-68     Citation Subset:  IM    
Affiliation:
Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA. mbaumann@intra.nida.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Animals
Behavior, Animal / drug effects*
Binding Sites / drug effects
Dialysis / methods
Dopamine / metabolism
Dose-Response Relationship, Drug
Drug Administration Routes
Excitatory Amino Acid Antagonists / metabolism*,  pharmacology
Ibogaine / analogs & derivatives*,  chemistry,  metabolism*,  pharmacology
Male
Neurosecretory Systems / drug effects
Rats
Rats, Sprague-Dawley
Serotonin / metabolism
Chemical
Reg. No./Substance:
0/Excitatory Amino Acid Antagonists; 0/noribogaine; 50-67-9/Serotonin; 83-74-9/Ibogaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The neurochemical basis for the behavioral effects of triadimefon.
Next Document:  18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mec...